In chronic lymphocytic leukaemia (CLL) patients, treatment with the Bruton tyrosine kinase inhibitor ibrutinib induces a rapid shift of tumour cells from lymph nodes (LN) to peripheral blood (PB). Here, we characterized in depth the dynamics of ibrutinib-induced inflammatory, transcriptional and cellular changes in different compartments immediately after treatment initiation in seven relapsed/refractory CLL patients. Serial PB and LN samples were taken before start and during the first 29 days of treatment. Changes in plasma inflammation-related biomarkers, CLL cell RNA expression, B-cell activation and migration markers expression, and PB mononuclear cell populations were assessed. A significant reduction of 10 plasma inflammation markers, the majority of which were chemokines and not CLL-derived, was observed within hours, and was paralleled by very early increase of CD19 + circulating cells. At the RNA level, significant and continuous changes in transcription factors and signalling molecules linked to B-cell receptor signalling and CLL biology was observed in both PB and LN CLL cells already after 2 days of treatment. In conclusion, ibrutinib seems to instantly shut off an ongoing inflammatory response and interfere with diverse sensitive pathways in the LN.
Treatment with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib leads to a temporary increase in the absolute lymphocyte count (ALC) in CLL patients, so-called "redistribution lymphocytosis". This phenomenon, common to all agents targeting the B-cell receptor (BCR) pathway, is explained by lymphocyte migration from nodal compartments, probably due to the disruption of signalling affecting adhesion factors in bone marrow and lymph nodes (LN) causing cell mobilization (Buchner et al, 2010) . The degree and time course of ibrutinib-induced lymphocytosis is variable, but occurs very early in almost half of the cases (Herman et al, 2014a) , making it reasonable to assume that crucial cellular events occur in the LN within hours after start of treatment. Understanding the dynamics of the cellular and humoral changes induced by ibrutinib-driven interference with sensitive pathways may contribute to the identification of yet unknown mechanisms of action of this drug.
We have observed during our years of clinical experience with ibrutinib that many patients describe an almost immediate sensation of improved well-being at start of therapy, i.e. before tumour regression occurs (unpublished observation) but the reason for this clinical observation has remained unexplained. To address this observation, this study assessed the early changes in plasma levels of 92 inflammationrelated biomarkers. Additionally, peripheral blood (PB) samples, taken as soon as 9 h after the first ibrutinib dose, and paired PB and LN samples taken at three time-points during the first 4 weeks of treatment were compared to pre-treatment samples. The expression of B-cell activation and migration markers was also assessed and the BCR signalling "off-target" effects of ibrutinib extensively studied. For the first time, the transcriptomic profile of sorted CLL cells from PB and LN cells was also examined in relation to ibrutinib treatment and expression in normal B cells.
Materials and methods

Patients and donors
Seven patients with relapsed or refractory CLL starting ibrutinib at the Haematology Department, Karolinska University Hospital, were included in the study. Patient characteristics are listed in Table I . The research project was approved by the local ethics committee and participating subjects gave written informed consent. PB samples were collected <1 week before treatment and then 9 h after the first dose on day 1 and after daily dosing on days 2, 4, 8, 15 and 29 of treatment. Fine needle aspiration of two enlarged LN identified by ultrasound was performed <1 week before treatment and at days 2, 8 and 29. To allow proper LN sampling, only patients with large lymphadenopathy were included. For the flow-cytometry analysis, the LN samples were pooled, while for the RNA sequencing only samples from one of the LN were used. IGHV mutational status was assessed as previously described (Palma et al, 2017) . Chromosomal abnormalities, TP53 gene mutations and ALC were determined by the hospital routine laboratory. PB samples from unidentified healthy donors (aged >60 years) were acquired from the hospital blood bank. PB from an X-linked agammaglobulinaemia (XLA) patient with a verified mutation in the BTK gene was acquired from the hospital Immunodeficiency Unit.
Flow cytometric characterization of lymphocyte profile and apoptosis PB was subjected to red blood cell lysis, then the cells washed once and re-suspended in Cell Staining Buffer (CSB) (BioLegend, San Diego, CA). See Data S1 for details of the staining procedures.
Flow cytometric characterization of lymphocyte subsets and proliferation
Peripheral blood mononuclear cells (PBMC) were isolated from whole heparinized blood by density gradient centrifugation using Ficoll-Hypaque gradient (GE Healthcare, Uppsala, Proximity Extension Assay (PEA)
PEA was performed using the Proseek â Multiplex Inflammation I 96996 format (Olink Bioscience, Uppsala, Sweden) (Assarsson et al, 2014) . See Data S1 for details and cut-off levels used for identification of altered levels. A complete list of the markers analysed is provided in Table SI .
FACS of normal B cells (from healthy donors)
For isolation of normal B-cell subsets, vital frozen PBMCs from healthy donors were thawed and subsequently Fc-blocked and stained as reported in the Data S1. Na€ ıve and memory B cells were purified as
RNA-sequencing and analysis
RNA-seq libraries were prepared from 5 to 10 9 10 3 FACS sorted cells using the TotalScript TM RNA-seq kit (Epicentre, Madison, WI) and sequenced on the Illumina platform (Illumina, San Diego, CA, USA). Reads were mapped to the human genome (Hg19) using STAR v2.5.2b (https://github.c om/alexdobin/STAR) and EdgeR (https://bioconductor.org/ packages/release/bioc/html/edgeR.html) was utilized to identify differentially expressed genes. For details, see Data S1.
Results
The expression of inflammation-related protein biomarkers in plasma changes significantly and at 6 different time points during treatment (9 h after treatment start; on days 2, 4, 8, 15 and 29). The expression of 23 molecules was significantly down-regulated ≥1 timepoints during treatment (Fig 1, left panel) , while no consistent increases were observed. CCL2 (MCP-1), CCL3 (MIP-1 alpha), CCL4 and CCL19 were already down-regulated by 9 h and at all subsequent time points, similar to IL10, TGFA (TGF-a) and LTA (TNF-b). The levels of CCL8 (MCP-2), CXCL6 and OSM (Oncostatin M) were also reduced by 9 h, whereas CSF1 (M-CSF), CXCL1, -10, -11, GDNF and TGFB1 (TGF-b1) were not significantly down-regulated until day 2, similar to three TNF superfamily members: the soluble, decoy receptor OPG (Osteoprotegerin; TNFRSF11B), the transmembrane receptors TNFSF14 (CD258) and TNFRSF9 (4-1BB; CD137), as well as the interleukin receptor IL10RB. The CLL marker CD5, similar to Urokinase Plasminogen Activator (PLAU, uPA), was not reduced until day 8, whereas CD6 was significantly down-regulated by day 4.
To investigate if concurrent changes in mRNA levels could be found, we subjected FACS-sorted PB/LN CLL cells and normal B cells (na€ ıve B and memory B) to RNA-sequencing (see Table SII for sample information). Correlation between samples was high overall (>0Á86 for all analysed samples) demonstrating high technical reproducibility and similarity between the samples ( Figure S1A ). Consistent with this, principal component analysis (PCA) displayed clear separation between normal B-cell subsets and CLL cells in PCA1 (Figure S1B) . We found no clear connection between PCA2 and lymphoid compartment, time after treatment, mutational status or other parameters ( Figure S1C ). Comparison of mRNA levels for the inflammation markers in sorted CLL cells revealed that the majority of the affected proteins did not show a corresponding decrease in transcript levels (Fig 1,  right panel) . Moreover, TNFSF14, CCL3 and CCL4 were more highly expressed in LN cells as compared to PB CLL cells. When CCL3 and CCL4 transcript levels in CLL LN cells were compared to na€ ıve-and memory-B cells from healthy donors, expression in CLL cells more resembled that of na€ ıve cells. Considerably higher OSM transcript levels were found in normal B lymphocytes as compared to CLL cells, whereas both CD5 and CD6 mRNAs were more abundant in tumour cells.
Transcriptional changes occur rapidly following Ibrutinib treatment
To investigate the global effect of ibrutinib treatment on RNA expression, we next compared pre-treatment (LN and/ or PB) to day 2 and day 29 of treatment to identify significant differences in RNA expression. This identified 357 genes (corrected P < 0Á01 and >2-fold change) with altered expression after start of ibrutinib treatment (Fig 2A and  Table SIII ). This revealed several genes previously linked to CLL pathobiology [including NOTCH1, EGR2, CD20 (MS4A1), RELB and CCL3]. Clear changes in RNA expression were observed as early as day 2 of treatment in both LN and PB CLL cells (Fig 2A cluster I -III and V-VI). These early effects include the majority of highly significant changes (Bonferroni corrected P < 0Á05 and >2-fold change) that interestingly were overall maintained in LN but not in PB at day 29 (Fig 2 cluster II) . Additionally, more gradual and less pronounced expression changes, often constituting down-regulations, could clearly be observed at day 29 (Fig 2A cluster IV and VII) .
To investigate the function of the affected genes, we analysed functional annotations using Metascape (www.metasca pe.org). Genes displaying rapid upregulation following ibrutinib treatment (Fig 2A cluster II-III ) displayed the strongest observed enrichments and were linked to energy production in mitochondria, ribosome assembly and translation ( Fig 2B) . Conversely, genes down-regulated after onset of ibrutinib treatment (Fig 2A cluster VI-VII) were associated with regulation of haematopoiesis, B-cell proliferation, leucocyte cell-cell adhesion and regulation of protein kinase activity ( Fig 2B) .
CLL cells from LN of untreated patients have previously been shown to display higher expression of genes downstream of BCR-and NFjB signalling as well as of E2F and MYC target genes (Herishanu et al, 2011) . To investigate if these previously defined genes were impacted by the ibrutinib treatment and similar differences between LN and PB could be observed in relapsed/refractory patients, we specifically investigated their expression. Several of these genes displayed significant changes at day 2/29 of treatment (Fig 2A and Figure S2A -D). When further analysed at the gene set level, LN CLL cells displayed significantly higher expression of BCR-, NFjB-and E2F-target genes than PB CLL cells ( Figure S2 ). In addition, ibrutinib treatment caused significant reduction of all four gene sets in LN albeit with different kinetics ( Figure S2 ). In PB, the BCR gene set displayed continued down-regulation over time while effects on E2F-and MYC-targets were only observed at day 2 of treatment.
Circulating CLL cells increase very early after treatment initiation
The ALC increase was significant at days 2, 8 and 15 (P < 0Á05) (Fig 3A) , the median increase at 9 h being 74% ( Fig 3B) . The absolute numbers of CD19 + cells changed accordingly ( Fig 3C) . Percentage numbers are reported in Table SII . The ALC peak varied between patients, occurring at day 2 in two patients (Patients 2 and 4), day 8 in two patients (Patients 3 and 5), day 15 in one (Patient 7) and day 29 in two others (Patients 1 and 6). The LN response is reported in Table I . No correlation was observed between the LN clinical response and either the ALC at baseline or the presence or absence of del(17p) or TP53 mutation. increased on day 2 (P = 0Á03), together with a trend towards increase in T-helper type 1 (Th1) cells (P = 0Á08). No surface expression of CTLA-4 was observed before or during ibrutinib treatment (data not shown).
Very Early Effects of Ibrutinib in CLL
Ibrutinib rapidly inhibits proliferation of CLL-and T-cells
No effect was seen on lymphocyte apoptosis in PB (Fig 3G-H) . At baseline, the median frequency of proliferating CLL cells was 2Á7% (range 0Á6-10Á8%), which remained unchanged on day 2 (median 2Á4%), while the absolute numbers increased substantially (median 1Á78 vs. 0Á62 9 10 9 /l, P = 0Á02). At day 8, proliferating CLL cells had significantly decreased (P = 0Á01) (Fig 3I-J) , while proliferating CD3 + T cells were not diminished until day 29 (P = 0Á03) (Fig 3K-L) . Proliferation decreased in both CD4 + and CD8 + T cells, however not significantly ( Figure S3B -C).
Changes in surface expression of cell activation and migration markers in different compartments
Of 18 surface B-cell activation and migration markers assessed in CLL cells from paired PB and LN samples, only CD23 was higher in LN compared to PB (P = 0Á02) at baseline. CD23 MFI was decreased in LN from day 2 onwards, while in PB only at day 29 (Fig 4A-B) . CD69 expression likewise decreased from day 8 onwards in both LN and PB (Fig 4A, C) . In contrast, CXCR4 seemingly increased over time in both LN and PB, but the change became significant only in PB at day 29 (Fig 4A, D) . We also observed reduced expression of CD5 (at day 29 in PB), CD20 (from day 2 in both PB and LN), CD25 (at day 29 in PB), CD40 (from day 8 in PB) and CD40L (at day 29 in PB) (Fig 4A) . No significant change was observed with regard to the expression of IgD, IgM, CD10, CD11a, CD27, CD38, CD49d, CD54, CD86, CD95 or CD200 in PB and LN ( Figure S4A ). For the T cells, the only marker which was significantly higher in LN compared to PB cells was CD69. No differences were observed for CD11a, CD40L, CD69, CD25 and CD95 ( Figure S4B ).
Effects on DC and monocyte subsets in peripheral blood
In five patients, DC and monocytes subsets at day 29 were compared to baseline ( Figure S5 ). Three patients had almost no detectable plasmacytoid DC (pDC) before treatment. At day 29, the percentage of pDC amongst DC increased in all patients, though not significantly (P = 0Á06) ( Figure S5C ). While the percentage of monocytes was unchanged during treatment (data not shown), a trend towards decrease in the percentage of CD16 + SLAN + monocytes was observed in all the patients (P = 0Á06) ( Figure S5E ); no consistent changes were observed in the CD16 + SLAN -monocyte population ( Figure S5F ).
Discussion
This is the first study to dissect the effect of ibrutinib at very early time points by extensively analysing plasma inflammation-related protein biomarkers. In addition, both PB and LN-resident cells were analysed in depth by flow-cytometry and RNA sequencing in 7 patients with relapsed/refractory disease and very poor prognostic factors. Figure 5 provides a summary of the changes observed. In plasma, we observed that a number of inflammatory chemokines were reduced after 9 h, while others decreased at 48 h and yet others not until after 1-2 weeks. Among those already down-regulated by 9 h were CCL3 and CCL4, which are considered prognostic in CLL (Sivina et al, 2011) . Our findings also suggest that these two well-known CLL chemokines may preferentially originate from LN-resident CLL cells. Interestingly, most of the down-regulated molecules are not expressed in FACS-sorted CLL cells, suggesting that ibrutinib may directly affect other cells than B/CLL cells also expressing BTK, or other sensitive kinases. Among molecules showing reduced expression after 9 h, and not expressed by CLL cells, are CCL2, CCL8, CCL19, CXCL6 and TGFA. CCL2 is produced by various cell types with monocytes/macrophages being the major source (Deshmane et al, 2009 ); CLL cells do not express CCL2 but CLL-exposed monocytes do (Schulz et al, 2011) .
Diminished expression of CCL19 as well as, later, of CXCL10 and -11 can be attributed to the ibrutinib-mediated inhibition of the variety of stromal cells secreting these chemokines (Davids & Burger, 2012) . IL10, which originates from monocytes (Maffei et al, 2013) , CLL (Drennan et al, 2017) and activated T cells (Herman et al, 2011) , was also down-regulated at 9 h. For CSF1, it was reported that ibrutinib blocks (TNFSF11 [RANKL])/CSF1-induced phosphorylation of BTK and PLCG2 in osteoclasts, resulting in diminished bone resorption activity, and also cytokine and chemokine secretion from osteoclasts and stromal cell cultures .
The majority of cytokines with significantly reduced plasma levels are pro-inflammatory, as also observed after 24 h by Niemann et al (2016) . As in our study, the expression of CCL2, CCL3, CCL4 and CXCL10 (IP-10) was found to be reduced in plasma from relapsed CLL patients after 28 days of acalabrutinib treatment (Byrd et al, 2016) . Considering that inflammatory cytokines might support CLL cell survival both in vitro and in vivo (Schulz et al, 2011) , their reduction might be interpreted as a treatment effect.
CLL cells from different compartments have been shown to display marked differences in gene expression in untreated patients (Herishanu et al, 2011) . While these differences were not as distinct in samples from relapsed/ refractory patients, they can be observed at the level of both individual genes and gene sets. Further, as expected from ibrutinib inhibiting BCR signalling, down-regulation of the BCR-, NFjB-, E2F-and MYC-targets defined by Herishanu et al (2011) could be observed following the start of treatment. Further in line with this, significant and continuous down-regulations were observed in both PB and LN CLL cells of several transcription factors (IRF5, EGR2 and EGR3) and signalling molecules (MS4A1/CD20, NOTCH1, RELB) linked to BCR signalling and/or CLL pathobiology (Burger et al, 2009; Hewamana et al, 2009; Yang et al, 2009; Pede et al, 2013; Landau et al, 2015) . Hence, ibrutinib as expected hits BCR targets as well as other CLL-related genes.
Interestingly, similar expression changes were observed in PB and LN CLL cells at day 2. However, while these changes were generally maintained or became more significant at day 29 of treatment in LN, the majority was abrogated in PB by day 29. This suggests that the changes observed in PB at day 2, at least in part, simply reflect the mobilization of LN CLL cells to PB and that the mobilized cells subsequently adopt a PB-like expression pattern. Hence, ibrutinib seemingly has a larger impact on LN CLL cells than on CLL cells in circulation. This would be consistent with active (BTK-mediated) BCR signalling mainly occurring in secondary lymphoid organs. It has been suggested that alterations in the translation regulation are part of the oncogenic mechanism in CLL (Yeomans et al, 2016) . Following ibrutinib treatment, we observed significantly increased expression of a host of ribosomal proteins (RPL21P28, RPL21, RPS27A etc), which essentially normalizes the expression of these genes to levels observed in normal B-cells, and a very significant enrichment of genes associated with peptide elongation. Our data therefore indicate that ibrutinib treatment results in protein translation more reminiscent of that of normal B cells.
As our LN samples were collected using fine needle aspirations, contamination of LN samples with blood cannot be ruled out, even if the overall consistency of LN expression profiles argues against this. However, this potentially explains the different gene expression pattern observed in the day 29 LN sample from Patient 7. Conversely, the difference observed in the day 29 PB sample from Patient 1 is probably due to continued influx of LN cells to PB.
The ALC increase was essentially instant and its persistence varied, probably due to the different patient baseline clinical characteristics (ALC, moderate vs. bulky lymphadenopathy) (Herman et al, 2014b) . We observed an increase in the number of proliferating CLL cells in PB on day 2, followed by a dramatic decrease at day 8, which extends previously published data (Cheng et al, 2014; Herman et al, 2014b; Woyach et al, 2014) . Circulating T cells did not decrease, but proliferating T cells decreased significantly at day 29, earlier than previously reported . We observed a temporary increase in CD69 + CD4 + cells at day 2, which cannot be fully explained.
As reported by others, changes in T cells, including decrease in expression of activation markers and immune checkpoints (Dubovsky et al, 2013; Niemann et al, 2016) , occur considerably later as compared to CLL-and other tumour microenvironment (TME) cells. No differences were observed between the LN and PB compartments in the expression of cell activation and migration markers at baseline, except for CD23 on CLL cells and CD69 on T cells. Due to the shortage of LN material, especially at the follow-up time points, proliferation markers were not assessed on the LN. CD23, IgE receptor and diagnostic markers in CLL (Kriston et al, 2015) , was, in addition, down-regulated in LN already at day 2. In healthy individuals, autoimmunity might be caused by CD23 + immature B cells responding to T-helper cells, promoting BCR signalling and survival (Chung et al, 2002; Perez-Andres et al, 2010) . The early down-regulation of CD23 expression in LN upon ibrutinib treatment suggests that it may be the most BCR-dependent, traditional CLL surface antigen and a good marker for reduced BCR signalling. On the contrary, CD5 expression remained high in LN CLL cells and decreased only in PB CLL cells at day 29. Indeed, CD5 expression is known to be mediated by BCR activation, its function being inducing tolerance in autoreactive B cells, inhibiting BCR-signalling and reducing cell expansion (Renaudineau et al, 2005; Mageed et al, 2012) . Changes in CD20 and CD69 were in line with previous observations (Herman et al, 2014a; Da Roit et al, 2015; Pavlasova et al, 2016; Skarzynski et al, 2016) . CD40-CD40L interaction induces B cell activation and blocks apoptosis independently of BCR signalling. In our study, CD40L expression on T cells was unaffected, but a decrease of CD40 on PB CLL cells was observed from day 8, accompanied by a reduction in CD40L at day 29. However, no increased apoptosis was observed.
CXCR4 and CD49d (ITGA4) are important lymphocyte trafficking regulators, with high expression on CLL cells being associated with poor clinical outcome (Pepper et al, 2015) . In our study, CD49d expression remained unchanged in both PB and LN CLL cells during treatment. It has been previously proposed that the CXCR4-CXCL12 axis causes the retention of CLL cells in lymphoid organs (Calissano et al, 2011) . We did not observe down-regulation of CXCR4 in the LN, suggesting that, in response to ibrutinib, CLL cells exit the LN independently of CXCR4 down-regulation in these patients. Further studies are needed to unravel the complex interaction between BCR signalling, chemokine signalling and the role of BTK in B-cell homing (Muggen et al, 2016) .
Of five patients, three had no pDCs before treatment, in line with previous data (Saulep-Easton et al, 2014) . Since TNF-a (TNF) secreted by CLL-or T cells in the TME can suppress pDC development (Saulep-Easton et al, 2014) , the observed expansion of the pDC population could be explained by ibrutinib reducing TNF-a production by T-or other TME cells (Herman et al, 2011) . Given the role of pDCs in shaping antiviral immune responses, this could potentially enhance immunity.
A trend towards decrease in CD16 + SLAN + monocytes, which produce high levels of TNF-a (Wong et al, 2012) , was observed at day 29. To elucidate whether this was directly depending on BTK-inhibition in monocytes, we measured SLAN expression on monocytes from a patient with XLA, a condition characterized by loss of functional BTK (Vetrie et al, 1993; Berglof et al, 2013) . Indeed, we observed extremely few SLAN + monocytes ( Figure S6 ), suggesting that their presence depends on BTK signalling and that the observed decrease in CD16 + SLAN + monocytes was related to ibrutinib treatment.
The small sample size is the major limitation of this study. A novel finding in our study was the almost immediate (within hours) shut-off of an inflammatory response, i.e. downregulation of a broad repertoire of chemokines, which may fit our clinical observation that patients can describe an almost immediate sensation of improved well-being after the first dose of ibrutinib (unpublished observation). In addition, our findings confirmed that, even shortly after treatment initiation, ibrutinib interferes with several pathways both in tumour cells and in the TME. This seems to occur mainly in the LN, where the major consistent and persistent changes in tumour cell gene expression were observed, while the effect on circulating CLL cells seems to be limited. Our data suggest that ibrutinib activity results from both on-target and off-target effects of BCR-inhibition, because non-BCR signalling pathways involving BTK also seem to be affected from the earliest onset. Moreover, we confirmed and profoundly expanded the relevance of BTK for chemokine synthesis, which might be therapeutically exploitable in future studies. 
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